In the end, Chiroscience Group plc (LSE:CRO) has emerged as a net beneficiary of the merger of Astra AB and Zeneca Group plc.

Following last week's announcement that the U.S. Federal Trade Commission has approved the merger, Zeneca agreed to the immediate return of global rights outside Japan to CRO's Chirocaine long acting local anesthetic. The deal provides CRO a windfall of £20 million ($32.6 million), partly as near term cancellation compensation and partly